跳到正文
Dr Amol Akhade· @SuyogCancer · X·· 1 天前评分90

durvalumab

正文 · 机器翻译

所以没人知道为什么 Durvalumab 有效而 Pembrolizumab 和 Nivo 在围手术期 MIBC 试验中失败。 @DrChoueiri @tompowles1 @HHammersMD @montypal @OncoAlert @myESMO #esmo26

2038 浏览 · 19 赞 · 10 转发 · 3 回复

会议摘要
2879RO按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上

Durvalumab plus definitive chemoradiotherapy versus definitive chemoradiotherapy in patients with locally advanced esophagus carcinoma: ARION PRODIGE 67 randomized phase 2 trial

https://esmocongress.esmo.org
4737RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上

Durvalumab (D) in Combination With BCG Induction and Maintenance (I+M) for BCG-Naïve, High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): Early Recurrence and Cystectomy-Free Survival in Patients (pts) With Papillary Only Tumours From POT

https://esmocongress.esmo.org
LBA2按 Presidential Symposium I 对上

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial

https://esmocongress.esmo.org
LBA26按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial

https://esmocongress.esmo.org
LBA3按 Presidential Symposium I 对上

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org
LBA37按 Proffered paper: Gynaecological cancers 对上

Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud

https://esmocongress.esmo.org
引用@
Infographic to show the cross trial comparisons of 3 phase III perioperative IO trials in MIBC Only one is positive. Why ? I don't know. Looking forward towards full data of 2 negative trials on day 1 #esmo26 @myESMO
在 X 查看被引用的帖子

来源:Dr Amol Akhade · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org